Myasthenia gravis: recent advances in immunopathology and therapy.
Myasthenia gravis is the most frequent acquired disorder of neuromuscular transmission. In the majority of cases, pathogenic antibodies against components of the postsynaptic muscle endplate membrane can be detected. In recent years there have been significant advances in the pathophysiological understanding and therapy of the disease. Areas covered: PubMed searches were conducted for the term 'myasthenia gravis' cross-referenced with the terms 'immunology', 'subgroups', 'antibody', 'ocular', 'thymoma', 'treatment' and 'thymectomy'. Additionally, we summarized the current state of immunopathology and therapy. Expert commentary: Immunological research defined new target antigens at the postsynaptic neuromuscular junction which along with clinical features allow a refined definition of disease subgroups. Overall the prognosis of myasthenia gravis with best possible symptomatic, immunosuppressive and supportive treatment is good but new immunomodulatory treatment options are developed for patients who do not respond well to the first line therapy. For most patients individually adapted long-term drug therapy is needed.
a Department of Neurology , Heinrich-Heine-University, Medical Faculty , Duesseldorf , Germany.
John-Ih
JI
Lee
a Department of Neurology , Heinrich-Heine-University, Medical Faculty , Duesseldorf , Germany.
Sebastian
S
Jander
D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy; D009157:Myasthenia Gravis / Q000276:immunology / Q000628:therapy; D011379:Prognosis; D009435:Synaptic Transmission / Q000276:immunology; D013934:Thymectomy
D007166:Immunosuppressive Agents
Myasthenia gravis; antibody; clinical subgroups; immunology; therapy